Select therapeutic use:
Indications for TEVETEN:
Monotherapy: not volume depleted: initially 600mg once daily. Usual range: 400–800mg/day given as a single dose or in two divided doses. Moderate-to-severe renal impairment: max 600mg daily.
Concomitant aliskiren in patients with diabetes.
Fetal toxicity may develop; discontinue if pregnancy is detected. Correct salt/volume depletion before beginning therapy or monitor closely. Monitor BP, renal function, electrolytes. Renal artery stenosis. Severe CHF. Neonates. Pregnancy (Cat.D); monitor. Nursing mothers: not recommended.
See Contraindications. Dual inhibition of the renin-angiotensin system with ARBs, ACEIs, or aliskiren may increase risk of hypotension, hyperkalemia, renal function changes; avoid. Avoid concomitant aliskiren in renal impairment (CrCl <60mL/min). May be antagonized by, and renal toxicity potentiated by NSAIDs, including COX-2 inhibitors; monitor renal function periodically in elderly and/or volume-depleted. May increase lithium levels; monitor.
Angiotensin II receptor blocker (ARB).
Viral infection, injury, fatigue, abdominal pain, hypertriglyceridemia, arthralgia, depression, urinary tract or upper respiratory tract infection, rhinitis, pharyngitis, coughing, hypotension, rhabdomyolysis (rare).
Hepatic. 98% protein bound.